The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2025
Association of Plasma p-tau181 and Cognition in Nondemented Subjects Without Aβ42/40 Positivity.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Aw Timothy Bang Hao, Leow Yi Jin, Kandiah Nagaendran
Аннотация
OBJECTIVES: Tau pathology is a hallmark of Alzheimer's disease and contributes to cognitive decline. This study investigated cross-sectional associations between plasma phosphorylated tau at threonine-181 (p-tau181) and cognitive performance in non-demented individuals without Aβ42/40 positivity.
METHODS: Baseline cross-sectional data from 893 participants in the Biomarkers and Cognition Study, Singapore (BIOCIS) were analyzed. Multiple linear regression models, adjusted for age, sex, years of education, Aβ42/40 ratio, APOE ε4 status, and cognitive diagnosis, were conducted.
RESULTS: Higher plasma p-tau181 levels were associated with poorer executive function, slower processing speed, and reduced visuospatial ability. No significant associations were found for global cognition or episodic memory.
CONCLUSIONS: These findings suggest that plasma p-tau181 may serve as a practical biomarker for early cognitive change in Alzheimer's disease. Plasma-based biomarkers may be especially valuable where CSF or PET imaging is less accessible. Longitudinal studies are needed to validate these results.
METHODS: Baseline cross-sectional data from 893 participants in the Biomarkers and Cognition Study, Singapore (BIOCIS) were analyzed. Multiple linear regression models, adjusted for age, sex, years of education, Aβ42/40 ratio, APOE ε4 status, and cognitive diagnosis, were conducted.
RESULTS: Higher plasma p-tau181 levels were associated with poorer executive function, slower processing speed, and reduced visuospatial ability. No significant associations were found for global cognition or episodic memory.
CONCLUSIONS: These findings suggest that plasma p-tau181 may serve as a practical biomarker for early cognitive change in Alzheimer's disease. Plasma-based biomarkers may be especially valuable where CSF or PET imaging is less accessible. Longitudinal studies are needed to validate these results.